While many observers focused on the effect the sale of its oncology business to Servier SA will have on Shire PLC, which is expecting a takeover offer from Takeda Pharmaceutical Co. Ltd., the deal is also a significant one for the privately held French group and its hopes to become a major player in cancer on both sides of the Atlantic. (Also see "Shire's Suitors: Takeda, Pfizer Seen As Likely To Bid; Amgen Could Enter Fray" - Scrip, 6 April, 2018.)
Servier is paying $2.4bn in cash for the unit, a price that is a little higher than analysts at Deutsche...








